WELL Health vs. Docebo: Better Tech Stock to Buy Right Now?

Let’s look at the recent performances and growth prospects of Well Health and Docebo to identify a better buy.

| More on:

Canadian equity markets have rebounded strongly over the last few weeks amid easing recession fears, with the S&P/TSX Composite Index rising 9.9% higher this year. Amid improving investors’ optimism, let’s assess which of WELL Health Technologies (TSX:WELL) and Docebo (TSX:DCBO) would be a better tech stock to buy now based on their recent quarterly performances and growth prospects.

WELL Health Technologies

Earlier this month, WELL Health reported an impressive second-quarter performance, with its top line growing by 42% to $243.1 million. An organic growth of 21% and acquisitions over the last four quarters drove its sales. It witnessed solid performances across its three segments. During the quarter, it had 1.4 million patient visits and 2.1 million patient interactions, representing a year-over-year growth of 38% and 48%, respectively.

Amid the top-line growth, its adjusted gross profits increased by 18% to $107.4 million. However, its gross profit margin declined from 53.1% to 44.2% amid the acquisition of lower-margin businesses. Further, its adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) increased by 11%, while adjusted EBITDA to WELL shareholders grew by 3%. It also generated $35.2 million of cash from its operations, thus helping it to pay off $14 million of debt, lowering its leverage ratio to 2.67.

Meanwhile, I expect the uptrend in WELL Health’s financials to continue amid its expanding addressable market and growth initiatives. The increased usage of virtual services, digitization of patient records, and adoption of software solutions in the healthcare segment have expanded its addressable market. The company is implementing advanced artificial intelligence tools, patient engagement technologies, and digital workflow integration, which could grow its market share and drive its financials in the coming years. It has also adopted several cost-cutting initiatives, which could improve its profitability.

Docebo

Docebo also reported an impressive second-quarter performance earlier this month, beating its guidance. Its topline grew by 22% to $53.1 million. The addition of 307 customers over the last four quarters and an increase of 9.7% in its average contract value drove its financials. Supported by its top-line growth, its adjusted EPS (earnings per share) grew by 85.7% to $0.26. The company also generated free cash flows of $8.45 million during the quarter, representing a 20% year-over-year increase.

The usage of digital learning tools in academics and businesses is growing, thus expanding Docebo’s addressable market. Meanwhile, the company is introducing artificial intelligence-powered features to enhance its customers’ experience. The company has signed long-term agreements with its customers, providing financial stability. Amid its solid second-quarter performance and growth initiatives, the company’s management expects its 2024 top line to grow 18-19% while its adjusted EBITDA margin could be around 15-15.5%.

Investors’ takeaway

Supported by its solid performances, WELL Health is up 19.2% this year, outperforming the broader equity markets. Despite its strong returns, the company trades at an attractive valuation, with its next-12-month price-to-earnings multiple at 16.8.

Meanwhile, Docebo has underperformed the broader equity markets this year, with its stock price losing 9.1%. Despite the decline in stock price, the company’s valuation looks expensive, with its NTM price-to-earnings multiple standing at 38.2. Although both companies offer high growth prospects, I am more bullish on WELL Health due to its cheaper valuation.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Rajiv Nanjapla has no position in any of the stocks mentioned. The Motley Fool recommends Docebo. The Motley Fool has a disclosure policy.

More on Investing

how to save money
Investing

The Best TSX Stock for Canadians to Buy With $1,000 Right Now

iShares S&P/TSX 60 Index ETF (TSX:XIU) could be a great starter investment for new investors in Canada.

Read more »

Canadian dollars are printed
Dividend Stocks

Beat the TSX With This Cash-Gushing Dividend Stock

Toronto-Dominion Bank (TSX:TD) stock could do well in the year ahead.

Read more »

monthly desk calendar
Dividend Stocks

Monthly Income: Top Dividend Stocks to Buy in November

Here are two of the best monthly dividend stocks in Canada you can buy in November 2024 and hold for…

Read more »

hand stacks coins
Investing

A Top TSX Stock to Buy Now for Real Wealth Later

Intact Financial (TSX:IFC) stock is a fantastic dividend-growth play for the next 15 years and beyond.

Read more »

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Thursday, November 14

The U.S. wholesale inflation data and Fed chair Jerome Powell’s remarks about the economy will remain on TSX investors’ radar…

Read more »

Man data analyze
Tech Stocks

3 Reasons Celestica Stock Is a Screaming Buy Now

These three reasons make Celestica stock a screaming buy for long-term investors.

Read more »

profit rises over time
Dividend Stocks

These 2 Dow Stocks Are Set to Soar in 2025 and Beyond

Two Dow Jones stocks are screaming buys but Canadians must hold them in an RRSP or RRIF to avoid paying…

Read more »

TFSA (Tax free savings account) acronym on wooden cubes on the background of stacks of coins
Dividend Stocks

How to Use Your TFSA to Earn Ultimate Passive Income

If you have a TFSA, then you have the key to creating ultimate passive income. All you need is a…

Read more »